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Abstract
Objectives—To characterize antiretroviral therapy (ART) adherence across different 
programmes and examine the relationship between individual and programme characteristics and 
incomplete adherence among ART clients in sub-Saharan Africa.
Design—A cross-sectional study.
Methods—Systematically selected ART clients (≥18 years; on ART ≥6 months) attending 18 
facilities in three countries (250 clients/facility) were interviewed. Client self-reports (3-day, 30-
day, Case Index ≥48 consecutive hours of missed ART), healthcare provider estimates and the 
pharmacy medication possession ratio (MPR) were used to estimate ART adherence. Participants 
from two facilities per country underwent HIV RNA testing. Optimal adherence measures were 
selected on the basis of degree of association with concurrent HIV RNA dichotomized at less than 
or greater/equal to 1000 copies/ml. Multivariate regression analysis, adjusted for site-level 
clustering, assessed associations between incomplete adherence and individual and programme 
factors.
Results—A total of 4489 participants were included, of whom 1498 underwent HIV RNA 
testing. Nonadherence ranged from 3.2% missing at least 48 consecutive hours to 40.1% having an 
MPR of less than 90%. The percentage with HIV RNA at least 1000 copies/ml ranged from 7.2 to 
17.2% across study sites (mean = 9.9%). Having at least 48 consecutive hours of missed ART was 
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the adherence measure most strongly related to virologic failure. Factors significantly related to 
incomplete adherence included visiting a traditional healer, screening positive for alcohol abuse, 
experiencing more HIV symptoms, having an ART regimen without nevirapine and greater levels 
of internalized stigma.
Conclusion—Results support more in-depth investigations of the role of traditional healers, and 
the development of interventions to address alcohol abuse and internalized stigma among 
treatment-experienced adult ART patients.
Keywords
antiretroviral therapy; HIV/AIDS; medication adherence; sub-Saharan Africa; Tanzania; Uganda; 
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Introduction
In low-income and middle-income countries, the number of people receiving antiretroviral 
therapy (ART) grew from 300 000 in 2002 to 9.7 million by the end of 2012, with the 
greatest increase in coverage occurring in sub-Saharan Africa with 7.5 million ART 
recipients [1]. This rapid scale-up of ART provision has contributed to a 30% decrease in 
the global number of HIV-related deaths between 2005 and 2012 [2].
Although these gains are impressive, they also highlight the continued importance of 
adherence to ART. Delayed initiation of therapy, incomplete adherence and early treatment 
discontinuation remain among the strongest predictors of incomplete viral suppression, 
disease progression and mortality among individuals living with HIV [3–8]. Although a 
2006 meta-analysis found that adherence levels in sub-Saharan Africa exceeded levels found 
among patients in developed countries [9], data from both low-income and high-income 
settings have raised concerns about declining adherence rates over time [10–14]. Factors 
often associated with incomplete adherence among adults in sub-Saharan Africa include 
patient-level characteristics (e.g. depression, alcohol use [15]), poor patient–provider 
interactions [16,17] and structural factors, including the cost of transport and distance to the 
health facility [18,19]. Less is known about how programme-level characteristics, for 
example, where ART clinics dispense drugs and if they require treatment support buddies 
prior to ART initiation, influence ART adherence.
This manuscript presents findings from the adherence component of a two-part study to 
examine retention in ART services [20] and adherence to ART among treatment-
experienced adults in Tanzania, Uganda and Zambia. The objectives of the adherence study 
were to characterize patient ART adherence levels across multiple programme settings and 
to examine the relationship between individual and programme-level characteristics and 
incomplete adherence among ART clients who were on ART for at least 6 months.
Ethical review
The study was reviewed and approved by the ethics review board of the US Centers for 
Disease Control and Prevention (CDC) and the six partner and national ethical review 
committees. The Partners Healthcare Institutional Review Board ceded review to FHI 360.
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Design and study setting
A cross-sectional study was conducted among ART patients from 18 facilities from 
Tanzania, Uganda and Zambia. In each country, six sites with a minimum cohort size of 300 
patients at the time of the protocol development (2006) were purposively chosen in order to 
fulfil the sample size requirement of 250 patients per study site and to explore the impact 
that different programme characteristics may have on retention and adherence outcomes (see 
supplemental Table 1, http://links.lww.com/QAD/A616). During study start-up, the study 
team found that one facility in Tanzania consisted of two adult ART clinics and recruited 
125 patients from both the adult-only clinic and the family clinic wherein adults sought care 
and treatment with their families.
Study participants and data collection
Patients attending the study sites who were at least 18 years of age at ART initiation, had 
initiated ART at least 6 months prior to data collection and spoke one of the study languages 
were eligible. Participants were systematically sampled (see supplemental Table 1, http://
links.lww.com/QAD/A616), and if a patient was ineligible, unwilling or unavailable, then 
the study teams selected the next ART patient attending the clinic. All selected patients 
underwent a screening and consent process by trained research interviewers and, if they 
consented, were interviewed. After the interview and clinic visit, the study teams collected 
adherence estimates from the patient’s healthcare providers (doctors, clinicians, nurses, lay 
workers, pharmacists) and abstracted data from the patient’s medical, pharmacy and 
laboratory records using structured data abstraction forms. Interviews were also held with 
the ART clinics managers regarding the site-level characteristics. At two sites in each 
country, the study team collected blood samples from all participants for HIV RNA testing. 
Data collection took place from May to October 2011.
Measures
Adherence measures—Participant adherence was assessed using self-report, provider 
report and pharmacy refill data. Participants reported their 3-day adherence using the Adult 
AIDS Clinical Trials Group (AACTG) measure specifying the numbers of tablets for each 
drug missed each day [21], followed by an aggregate question of how many ART tablets 
missed in the previous 30 days. Both of these measures were calculated by dividing the 
number of missed tablets by the total number of ART pills over the specified time period. 
The interviewer also asked the three-question CASE Adherence Index Scale [22], with a 
composite score of more than 10 indicating good adherence, and the 30-day visual analogue 
scale (VAS) [23], with zero indicating complete nonadherence and 100 indicating perfect 
adherence. To understand patterns of missed ART, we constructed a missed at least 48 
consecutive hours measure from two questions about missed tablets in the past 3 months. 
Following the participant’s clinical visit, the interviewer asked all healthcare providers who 
interact with patients on adherence to estimate, based on the provider’s knowledge of the 
patient and their medical record, the proportion of time the participant had taken his/her 
drugs in the past month. In cases wherein multiple providers were interviewed, the lowest 
adherence estimate was taken for analysis. A Pharmacy Medication Possession Ratio (MPR) 
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was also constructed from the pharmacy refill data by summarizing the number of pills 
dispensed to participants in the 6 months prior to the interview divided by the total number 
of pills the participants should have received during that time.
Independent variables—Basic demographic variables collected included age, sex, 
marital status and the demographic and health survey’s wealth index (see supplemental 
Table 2, http://links.lww.com/QAD/A616) [24–27].
For psychosocial factors, we assessed stigma using five yes/no questions from the 
Internalized AIDS Stigma Scale (IA-RSS) [28,29] that resulted in two factors retained with 
very good fit [with a root mean squared error of approximation (RMSEA) of 0.03, 95% 
confidence interval (95% CI) 0.02–0.05] and perfect reliability (Tucker and Lewis’ 
reliability coefficient = 1). One factor consisted of three questions on internalized stigma 
(Chronbach’s alpha = 0.78) and the second factor consisted of two questions on disclosure 
stigma (Chronbach’s alpha = 0.72). Country-specific medians were used as the cutoff points 
to dichotomize responses into high (>median) versus low stigma.
The Hopkins Symptoms Checklist depression subscale (HSCL-15) was used to assess 
symptoms of depression, using the standard cut-off of 1.75 [30] with good fit (RMSEA 
0.055, 95% CI 0.053–0.058), reliability (Tucker and Lewis’s reliability coefficient = 0.90) 
and internal consistency (Chronbach’s alpha = 0.84).
Social support was assessed using nine questions from the Duke University, University of 
North Carolina Functional Social Support Questionnaire [31,32] and an added tenth question 
on receiving help to remember to take one’s ART. Exploratory and confirmatory factor 
analysis identified a two-factor model with adequate fit (RMSEA 0.097, 95% CI 0.093–
0.10) and reliability (Tucker and Lewis’s reliability coefficient = 0.83). The first factor, 
Social Support Care, consisted of seven questions about social support (Chronbach’s alpha = 
0.76) and the second factor, Social Support Help, consisted of four questions about 
instrumental help (Chronbach’s alpha = 0.78). Scores in the lowest tenth percentile were 
categorized as having low levels of social support (see supplemental Table 2, http://
links.lww.com/QAD/A616).
The four yes/no questions regarding alcohol use [cutting down, annoyance by criticism, 
guilty feeling and eye-openers (CAGE)] were used to assess alcohol abuse or dependency. 
Summed scores at least 2 were considered positive for alcohol abuse/dependency [33,34]. 
Other psychosocial variables assessed included having ever visited a traditional healer/
herbalist because of HIV (yes/no), having ever disclosed one’s HIV status and the average 
cost and time it took participants to reach the clinic.
The ART-related variables abstracted from the medical charts included current ART 
regimen, date of ART initiation and pre-ART initiation WHO stage and CD4+ cell count. In 
addition, we analysed participants’ self-reported daily pill burden and the 20-item HIV 
Symptom Index (see supplemental Table 2, http://links.lww.com/QAD/A616) [35].
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The programme characteristics assessed during the ART clinic manager interviews included 
background information on the level, type, size and location of the HIV facility; and how the 
clinic dispensed ART and supported medication adherence (e.g. frequency of ART refills).
Analysis—Analysis was performed using SAS 9.3 and STATA 11.2. The analysis plan, 
prepared before the database was locked, included predetermined cut-offs for outcome and 
predictor variables with a primary focus on perfect (100%) versus incomplete adherence. 
These predetermined cutoffs were used to summarize the prevalence of adherence across the 
different measures.
To identify individual modifiable risk factors and programme characteristics associated with 
incomplete ART adherence, a multiple mixed effects logistic regression model was used for 
the adherence measure that correlated best with the HIV RNA measurement. The model 
contained fixed effects for all factors of interest and a random intercept term effect for the 
mean adherence at each site. Cut-offs for the adherence measures were selected on the basis 
of receiver operating characteristic (ROC) analysis with HIV RNA at least 1000 copies/ml 
as the reference standard. The model was constructed using a hierarchical stepwise 
procedure, with individual-level factors associated at the 0.10 level added first, followed by 
the programme characteristics significant at the 0.20 level. The model was simplified using 
step-wise deletion retaining only significant factors and interactions at 0.05. The estimates 
were corrected for predictor data missing using multiple imputations (see supplemental 
Table 1, http://links.lww.com/QAD/A616) [36].
Results
A total of 6825 ART clients were screened for eligibility at the participating sites. Of these, 
1848 were ineligible (1523 initiated ART <6 months ago, 729 were <18 years of age and 
783 did not speak one of the study languages; these categories were not mutually exclusive). 
Out of the 4977 eligible, 482 (9.7%) declined to participate, leaving 4495 participants who 
consented and completed the interview. During data cleaning, the team found six 
participants with ART initiation dates that were less than 6 months prior to the interview, 
leaving 4489 participants for the final analysis.
Programme characteristics
Nineteen ART clinics from 18 facilities were included in the analysis, seven sites in 
Tanzania (the facility consisting of two different models of care was considered as two 
separate sites), six sites in Uganda and six sites in Zambia (see supplemental Table 3, http://
links.lww.com/QAD/A616). Slightly more than half of the health facilities were government 
facilities. Nongovernmental facilities were either faith-based or run by a nonreligious 
nongovernmental organization (NGO) with more NGO-supported facilities in Uganda 
compared with Tanzania and Zambia. More than two-thirds of the sites were located in an 
urban setting and eight sites had less than 2000 ART patients (range: 350–1967), seven sites 
between 2000 and 4000 patients (range: 2095–3989) and four had more than 4000 patients 
on ART (range: 4807–7471).
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Characteristics of the analysis population
Of the 4489 participants, 68% were female, 56% were married/cohabitating and the average 
age was 40 years (Table 1). The majority of participants had started ART more than 2.2 
years ago (75%), had a pre-ART CD4+ cell count of 250 cells/μl or less (67%) and were 
currently taking zidovudine (ZDV), lamivudine (3TC) and nevirapine (NVP)/efavirenz 
(EFV) (49%).
Proportion with incomplete adherence
Results from the self-reported measures of adherence found that 3.2% (141/4425) of 
participants missed at least 48 consecutive hours of ART in the past three months and 58% 
(2599/4450) reported taking less than 100% of their ART in the past 30 days using a VAS 
(Table 2). Providers estimated that 13.5% of participants were less than 80% adherent and 
71.3% were less than 100% adherent in the past 30 days. The pharmacy MPR data found 
that 40% (1634/4070) of participants had less than 90% of their ART during the previous 6 
months.
Selection of optimal adherence measures based on association with virologic failure
One thousand, four hundred and ninety-eight participants received HIV RNA testing and 
were younger, on ART for less time and had different ART regimens, compared with those 
who had not received testing. The proportion of participants with at least 1000 copies/ml 
ranged across the testing sites from 7.2 to 17.2% (mean 9.9%). Using the ROC curve 
analysis cutoff points, only three adherence measures were significantly related to virologic 
failure (Table 3), with at least 48 consecutive hours of missed ART having the strongest 
association with an odds ratio (OR) of 2.86 (95% CI 1.56–5.26) followed by the pharmacy 
MPR less than 90% (OR 1.47, 95% CI 1.02–2.15) and the healthcare provider report less 
than 98% (OR 1.57, 95% CI 1.02–2.41). On the basis of these results and previous evidence 
of the importance of treatment interruptions as a predictor of virologic failure and resistance 
[37,38], combined with provider estimates most likely reflecting a clinical assessment rather 
than pill-taking behaviours [39–41], the team selected the variable at least 48 consecutive 
hours of missed ART as the primary outcome variable to examine the factors associated 
with incomplete adherence.
Factors associated with incomplete adherence
During univariate analysis, significant associations at the 0.10 level between individual 
demographic and psychosocial characteristics and incomplete adherence were male sex, 
high levels of internalized stigma, screening positive for depression, low levels of social 
support care, screening positive for alcohol abuse, having ever consulted a traditional healer/
herbalist because of HIV and having a current ART regimen that does not contain NVP 
(Table 4). In terms of programme characteristics, significant associations at the 0.20 level 
were having routine ART refills every 2–3 months compared with once a month, the level 
and type of health facility, urban location and not offering community-based distribution of 
ART.
The final multiple regression model found five independent variables associated with 
incomplete adherence (Table 5): having high levels of internalized stigma, screening 
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positive for alcohol abuse, ever consulting a traditional healer/herbalist because of HIV and 
having higher numbers of HIV-related symptoms. The analysis also found that having an 
ART regimen containing NVP was protective against incomplete adherence and a lack of 
social support care was marginally associated with incomplete adherence. The final model 
did not include any of the programme characteristics.
Discussion
This first multicountry study of individual and programme-level factors related to adherence 
among patients in sub-Saharan Africa on ART for at least 6 months found that social and 
behavioural factors, including HIV stigma and alcohol abuse, are associated with lower 
ART adherence. These data support the development of interventions to address high-risk 
alcohol use and internalized stigma as potential ways to enhance ART adherence and HIV-
related health outcomes. The findings also underscore the need to examine how traditional 
healers may support or hinder ART adherence. Furthermore, these data highlight the 
variability of existing adherence measures and the need for both accurate research and 
programme-level methods for assessing pill-taking behaviours in order to inform 
programme strategies and assess intervention impact.
This research is also the first multicountry study to examine self-reported prevalence of 
missed antiretroviral drugs for at least 48 consecutive hours, in addition to the more 
common adherence measures of 3 and 30-day self-reports, pharmacy refill and provider 
reports. Similar to previous studies, the adherence estimates varied greatly with the 3 and 
30-day aggregate questions generating the lowest estimates of missed ART [42] and 
corresponding poorly with virologic failure. The study results also reaffirm findings that 
pharmacy MPRs are associated with virologic failure [43], and contrary to other studies 
[39,41], found that provider estimates were also associated with virologic failure. Providers, 
including clinicians, pharmacists and adherence counsellors, gave their adherence estimates 
after a patient visit based on their knowledge of the patient and the patient’s medical record. 
As such, their assessment presumably reflects a combination of factors including knowledge 
of patient behaviours as well as clinical and laboratory treatment response prior to the 
assessment. Similarly, the pharmacy MPR takes into account patient’s medication refills 
over a 6-month time period capturing the maximum adherence a patient may achieve rather 
than actual pill-taking behaviours. Although only able to identify 11% of virological failures 
in our cross-sectional assessment, the strength of the relationship between the at least 48 
consecutive hours measure with virologic failure is consistent with several observations that 
patterns of adherence, namely interruptions during otherwise good adherence, is an 
important cause of virologic failure [37,38].
This is also the first study to examine the factors associated with incomplete adherence 
using at least 48 consecutive hours of missed ART as the main outcome. The factor most 
strongly related to incomplete adherence was having ever consulted a traditional healer or 
herbalist because of HIV. About three-quarters of the 253 participants who reported having 
ever visited a traditional healer or herbalist were from Tanzania. During data collection, a 
famous healer in the Manyara District of Tanzania was offering a liquid cure for chronic 
illnesses including HIV/AIDS [44,45]. Although our questionnaire did not investigate 
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details regarding the healer, this finding does contribute to a growing body of research on 
the role that traditional healers and alternative medicines may have in delaying HIV testing 
and care-seeking behaviours [46–48] and influencing sustained HIV ART adherence [49–
52].
This research also reinforces findings that alcohol abuse [53,54] and HIV stigma [55] are 
broad and consistent correlates of ART adherence. The CAGE questionnaire is a concise 
four-question tool that may be incorporated into clinic assessments to identify ART 
recipients who may benefit from alcohol counselling interventions. More than one-third of 
participants reported high levels of internalized stigma defined as feelings of worthlessness, 
shame and guilt because of one’s HIV-positive status, despite the fact that most of the 
participants in this research had initiated ART more than 2 years earlier. Stigma is 
associated with lower rates of HIV disclosure, which can compromise adherence due to both 
concealing the medication and preventing access to social support [56–58]. Several 
qualitative studies have found social support to be critical for people to overcome barriers, 
particularly structural and economic barriers, to adherence [16,59–61]. Although this study 
did not find a significant relationship between structural barriers (e.g. transport costs to the 
clinic) and adherence, we did find that people with lower levels of social support care were 
more likely to have missed at least 48 consecutive hours of ART in the past 3 months (P < 
0.054).
Other factors related to incomplete adherence include having a greater burden of HIV-
related symptoms as well as an ART regimen that did not include NVP. Women of 
childbearing age and/or actively considering pregnancy were given NVP rather than EFV 
during the study period out of concern for EFV-related teratogenicity. Pregnancy has been 
shown to positively impact adherence in some but not all studies [62,63]. Although our 
analysis controlled for age and sex, we did not control for fertility desire or pregnancy 
intention. Therefore, the association between NVP and adherence may be confounded by 
preferential prescription of NVP to patients pregnant or considering pregnancy. 
Alternatively, higher adherence to NVP may be related to differing side effect profiles for 
NVP versus EFV, which was not fully controlled for in our analysis.
These factors –— internalized stigma, alcohol abuse, low levels of social support, visiting 
traditional healers and burden of HIV symptoms –— all give insights into the challenges 
treatment-experienced people living with HIV are dealing with on a daily basis even after 
several years of taking ART. The current biomedical approach to HIV treatment is that you 
take your ART regularly, you feel better and your life returns to ‘normal’. This script, 
however, does not always play out in people’s lives [64]. Tsai et al. [65] suggest that stigma 
in low-resource settings is tied with concepts of disability, economic incapacity and death, 
and that poverty alleviation strategies may be effective in reducing HIV-related stigma. 
More innovative research around self-identity and living with HIV as a chronic illness [64], 
combined with strategies to overcome and reduce stigma through programmes, such as 
poverty alleviation that can restore one’s identity, are needed, as HIV services seek to 
support life-long ART adherence and healthy outcomes among people living with the virus.
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The strengths of this study include representation from 19 ART clinics in 18 different health 
facilities in three countries using standardized data collection tools, an HIV RNA test among 
a subsample and a systematic sampling strategy among ART patients who initiated therapy 
at least 6 months prior to data collection. Although the number of participating sites is one 
of the study’s strengths, 19 ART clinics were too few to fully examine the association of 
programme characteristics with ART adherence. The cross-sectional design of the study 
restricts interpretations to associations rather than temporal relationships and causation. For 
example, virologic failure could have happened prior to the time frame of 3 and 30-days 
captured by the self-reported adherence measures, potentially explaining the low overall 
correlations we found between the different measures of adherence and virologic failure. 
Study sites were also not randomly selected, and this could have introduced selection bias. 
However, the selection was conducted in consultation with country-specific stake-holders 
and aimed to balance site characteristics that might influence retention and adherence. 
Within study sites, we were also unable to assess whether ART clients who declined to 
participate differed from those who chose to participate.
Conclusion
These data support the importance of social and behavioural factors on impacting adherence 
in resource-limited settings. Interventions to reduce alcohol abuse and stigma should be 
paramount and efforts to enhance social support may improve adherence. The findings also 
support a more in-depth investigation of the role that traditional healers and alternative 
medicines play in how adults living with HIV in sub-Saharan Africa manage their infection. 
Although the study did not find evidence that programme characteristics relate to incomplete 
adherence, there is a need to critically assess programme approaches, as well as develop 
interventions to address alcohol abuse and internalized stigma, among treatment-
experienced adult ART clients.
Acknowledgements
Y.D.M., J.A.D, K.T, E.V.P, G.P. K., F.W.M, M.M., D.R.B, R.C., J.M and O.K. designed the study. J.A.D., O.K., 
J.M., R.C. and D.R.B. wrote the first draft of the article. J.M and S.T. performed the statistical analysis. A.A., S.A. 
and J.K. contributed critical revisions to the analysis and interpretation. All authors contributed to the writing of the 
final draft.
This research has been supported by the President’s Emergency Plan for AIDS Relief (PEPFAR) through the 
Centers for Disease Control and Prevention (CDC) and the Health Resources & Services Administration (HRSA) 
under the terms of the contract no. 2006-N-08428 with FHI 360. The findings and conclusions in this report are 
those of the author(s) and do not necessarily represent the official position of CDC, HRSA or any other federal 
agency or office.
The authors gratefully acknowledge the invaluable contributions of the people living with HIV who participated in 
this study and to the staff of the health facilities where the research was conducted. We also gratefully acknowledge 
Dr Seymour Williams of CDC who was instrumental in designing the study and to the study coordinators who 
oversaw study implementation in each of the countries, Drs Marysia Antony Tukai, Esther Birabwa and Sebastian 
Hachizovu.
References
1. WHO. Global update on HIV treatment 2013: results, impact and opportunities: WHO report in 
partnership with UNICEF and UNAIDS. WHO; Geneva, Switzerland: 2013. 
Denison et al. Page 9













2. UNAIDS. report: UNAIDS report on the global AIDS epidemic 2013. Joint United Nations 
Programme on HIV/AIDS (UNAIDS); Geneva, Switzerland: 2013. 
3. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Nonadherence 
to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001; 15:1181–1183. 
[PubMed: 11416722] 
4. Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication 
adherence and the development of class-specific antiretroviral resistance. AIDS (London, England). 
2009; 23:1035.
5. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, et al. Adherence to highly 
active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South 
African adults. J Acquir Immune Defic Syndr. 2006; 43:78–84. [PubMed: 16878045] 
6. Babiker AG, Emery S, Fätkenheuer G, Gordin FM, Grund B, Lundgren JD, et al. Considerations in 
the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) 
study. Clin Trials. 2013; 10:S5–S36. [PubMed: 22547421] 
7. Braitstein P, Brinkhof M, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-
infected patients in the first year of antiretroviral therapy: comparison between low-income and 
high-income countries. Lancet. 2006; 367:817–824. [PubMed: 16530575] 
8. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up of highly 
active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006; 
367:1335–1342. [PubMed: 16631912] 
9. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral 
therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006; 296:679–690. 
[PubMed: 16896111] 
10. Byakika-Tusiime J, Crane J, Oyugi JH, Ragland K, Kawuma A, Musoke P, et al. Longitudinal 
antiretroviral adherence in HIV+ Ugandan parents and their children initiating HAART in the 
MTCT-Plus family treatment model: role of depression in declining adherence over time. AIDS 
Behav. 2009; 13:82–91. [PubMed: 19301113] 
11. Parruti G, Manzoli L, Toro PM, D’amico G, Rotolo S, Graziani V, et al. Long-term adherence to 
first-line highly active anti-retroviral therapy in a hospital-based cohort: predictors and impact on 
virologic response and relapse. AIDS Pat Care STDs. 2006; 20:48–56.
12. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to 
antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus: infected 
persons in clinical trials. Clin Infect Dis. 2002; 34:1115–1121. [PubMed: 11915001] 
13. Liu H, Miller LG, Hays RD, Golin CE, Wu T, Wenger NS, et al. Repeated measures longitudinal 
analyses of HIV virologic response as a function of percentage adherence, dose timing, genotypic 
sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006; 41:315–322. [PubMed: 
16540932] 
14. Gill CJ, Hamer DH, Simon JL, Thea DM, Sabin LL. No room for complacency about adherence to 
antiretroviral therapy in sub-Saharan Africa. AIDS. 2005; 19:1243–1249. [PubMed: 16052078] 
15. Mayston R, Kinyanda E, Chishinga N, Prince M, Patel V. Mental disorder and the outcome of 
HIV/AIDS in low-income and middle-income countries: a systematic review. AIDS. 2012; 
26:S117–S135. [PubMed: 23303434] 
16. Watt MH, Maman S, Golin CE, Earp JA, Eng E, Bangdiwala SI, et al. Factors associated with self-
reported adherence to anti-retroviral therapy in a Tanzanian setting. AIDS Care. 2010; 22:381–
389. [PubMed: 20390519] 
17. Siedner MJ, Haberer JE, Bwana MB, Ware NC, Bangsberg DR. High acceptability for cell phone 
text messages to improve communication of laboratory results with HIV-infected patients in rural 
Uganda: a cross-sectional survey study. BMC Med Inform Decis Mak. 2012; 12:56. [PubMed: 
22720901] 
18. Lankowski AJ, Siedner MJ, Bangsberg DR, Tsai AC. Impact of geographic and transportation-
related barriers on HIV outcomes in sub-Saharan Africa: a systematic review. AIDS Behav. 2014; 
18:1199–1223. [PubMed: 24563115] 
Denison et al. Page 10













19. Kagee A, Remien R, Berkman A, Hoffman S, Campos L, Swartz L. Structural barriers to ART 
adherence in Southern Africa: challenges and potential ways forward. Glob Public Health. 2011; 
6:83–97. [PubMed: 20509066] 
20. Koole O, Tsui S, Wabwire-Mangen F, Kwesigabo G, Menten J, Mulenga M, et al. Retention and 
risk factors for attrition among adults in antiretroviral treatment programmes in Tanzania, Uganda 
and Zambia. Trop Med Int Health. 2014; 19:1397–1410. [PubMed: 25227621] 
21. Chesney MA, Ickovics J, Chambers D, Gifford A, Neidig J, Zwickl B, et al. Self-reported 
adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG 
adherence instruments. AIDS Care. 2000; 12:255–266. [PubMed: 10928201] 
22. Mannheimer S, Mukherjee R, Hirschhorn L, Dougherty J, Celano S, Ciccarone D, et al. The CASE 
adherence index: a novel method for measuring adherence to antiretroviral therapy. AIDS Care. 
2006; 18:853–861. [PubMed: 16971298] 
23. Giordano TP, Guzman D, Clark R, Charlebois E, Bangsberg D. Measuring adherence to 
antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials. 2004; 
5:74–79. [PubMed: 15116282] 
24. Central Statistical Office MoH. Tropical Diseases Research Centre. University of Zambia, Inc MI. 
Zambia Demographic and Health Survey 2007. CSO and Macro International Inc Calverton; 
Maryland: 2009. 
25. Statistics, UBo; ICF International. Uganda Demographic and Health Survey 2011. UBOS and 
Calverton; Maryland: ICF International Inc; Kampala, Uganda: 2012. 
26. National Bureau of Statistics (NBS) [Tanzania] and ICF Macro. Tanzania demographic and health 
survey 2010. NBS and ICF Macro; Dar es Salaam, Tanzania: 2011. 
27. Rutstein Shea O and Kiersten Johnson. The DHS wealth index. ORC Macro; Calverton, Maryland: 
2004. DHS Comparative Reports No. 6.
28. Simbayi LC, Kalichman S, Strebel A, Cloete A, Henda N, Mqeketo A. Internalized stigma, 
discrimination, and depression among men and women living with HIV/AIDS in Cape Town, 
South Africa. Soc Sci Med. 2007; 64:1823–1831. [PubMed: 17337318] 
29. Kalichman SC, Simbayi LC, Cloete A, Mthembu PP, Mkhonta RN, Ginindza T. Measuring AIDS 
stigmas in people living with HIV/AIDS: the Internalized AIDS-Related Stigma Scale. AIDS 
Care. 2009; 21:87–93. [PubMed: 19085224] 
30. Kaaya SF, Fawzi M, Mbwambo J, Lee B, Msamanga G, Fawzi W. Validity of the Hopkins 
Symptom Checklist-25 amongst HIV-positive pregnant women in Tanzania. Acta Psychiatr Scand. 
2002; 106:9–19. [PubMed: 12100343] 
31. Broadhead W, Gehlbach SH, De Gruy FV, Kaplan BH. The Duke-UNC Functional Social Support 
Questionnaire: measurement of social support in family medicine patients. Med Care. 1988; 
26:709–723. [PubMed: 3393031] 
32. Antelman G, Kaaya S, Wei R, Mbwambo J, Msamanga GI, Fawzi WW, et al. Depressive 
symptoms increase risk of HIV disease progression and mortality among women in Tanzania. J 
Acquir Immune Defic Syndr. 2007; 44:470–477. [PubMed: 17179766] 
33. Claassen J. The benefits of the CAGE as a screening tool for alcoholism in a closed rural South 
African community. South Afr Med J. 1999; 89:976.
34. Samet JH, Phillips SJ, Horton NJ, Traphagen ET, Freedberg KA. Detecting alcohol problems in 
HIV-infected patients: use of the CAGE questionnaire. AIDS Res Hum Retroviruses. 2004; 
20:151–155. [PubMed: 15018702] 
35. Justice A, Holmes W, Gifford A, Rabeneck L, Zackin R, Sinclair G, et al. Development and 
validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001; 54:S77–S90. 
[PubMed: 11750213] 
36. Royston P. Multiple imputation of missing values. Stata J. 2004; 4:227–241.
37. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, et al. Treatment 
interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination 
antiretroviral therapy in Kampala, Uganda. AIDS. 2007; 21:965–971. [PubMed: 17457090] 
38. Genberg BL, Wilson IB, Bangsberg DR, Arnsten J, Goggin K, Remien RH, et al. Patterns of 
antiretroviral therapy adherence and impact on HIV RNA among patients in North America. 
AIDS. 2012; 26:1415–1423. [PubMed: 22767342] 
Denison et al. Page 11













39. Bangsberg DR, Hecht FM, Clague H, Charlebois ED, Ciccarone D, Chesney M, et al. Provider 
assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr. 2001; 
26:435–442. [PubMed: 11391162] 
40. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease 
inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133:21–30. 
[PubMed: 10877736] 
41. Gross R, Bilker WB, Friedman HM, Coyne JC, Strom BL. Provider inaccuracy in assessing 
adherence and outcomes with newly initiated antiretroviral therapy. AIDS. 2002; 16:1835–1837. 
[PubMed: 12218400] 
42. Bärnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell M-L. Interventions to 
increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. 
Lancet Infect Dis. 2011; 11:942–951. [PubMed: 22030332] 
43. McMahon JH, Jordan MR, Kelley K, Bertagnolio S, Hong SY, Wanke CA, et al. Pharmacy 
adherence measures to assess adherence to antiretroviral therapy: review of the literature and 
implications for treatment monitoring. Clin Infect Dis. 2011; 52:493–506. [PubMed: 21245156] 
44. Ashforth A. AIDS, religious enthusiasm and spiritual insecurity in Africa. Global Pub Health. 
2011; 6:S132–S147. [PubMed: 21819313] 
45. Thielman NM, Ostermann J, Whetten K, Whetten R, Itemba D, Maro V, et al. Reduced adherence 
to antiretroviral therapy among HIV-Infected Tanzanians seeking cure from the Loliondo Healer. J 
Acquir Immune Defic Syndr. 2014; 65:e104–e109. [PubMed: 24525471] 
46. Audet CM, Blevins M, Rosenberg C, Farnsworth S, Salato J, Fernandez J, et al. Symptomatic HIV-
positive persons in rural Mozambique who first consult a traditional healer have delays in HIV 
testing: a cross-sectional study. J Acquir Immune Defic Syndr. 2014; 66:e80–e86. [PubMed: 
24815853] 
47. Audet CM, Sidat M, Blevins M, Moon TD, Vergara A, Vermund SH. HIV knowledge and health-
seeking behavior in Zambezia Province, Mozambique. J Soc Asp HIV/AIDS. 2012; 9:41–46.
48. Okome-Nkoumou M, Okome-Miame F, Kendjo E, Obiang G-P, Kouna P, Essola-Biba O, et al. 
Delay between first HIV-related symptoms and diagnosis of HIV infection in patients attending 
the internal medicine department of the Fondation Jeanne Ebori (FJE), Libreville, Gabon. HIV 
Clin Trials. 2005; 6:38–42. [PubMed: 15765309] 
49. Musheke M, Bond V, Merten S. Individual and contextual factors influencing patient attrition from 
antiretroviral therapy care in an urban community of Lusaka, Zambia. J Int AIDS Soc. 2012; 15:1–
9. [PubMed: 22713354] 
50. Gourlay A, Birdthistle I, Mburu G, Iorpenda K, Wringe A. Barriers and facilitating factors to the 
uptake of antiretroviral drugs for prevention of mother-to-child transmission of HIV in sub-
Saharan Africa: a systematic review. J Int AIDS Soc. 2013; 16:18588. [PubMed: 23870277] 
51. Littlewood RA, Vanable PA. A global perspective on complementary and alternative medicine use 
among people living with HIV/AIDS in the era of antiretroviral treatment. Curr HIV/ AIDS Rep. 
2011; 8:257–268. [PubMed: 21822625] 
52. George G, Chitindingu E, Gow J. Evaluating traditional healers knowledge and practices related to 
HIV testing and treatment in South Africa. BMC Int Health Hum Rights. 2013; 13:45. [PubMed: 
24152384] 
53. Nakimuli-Mpungu E, Bass JK, Alexandre P, Mills EJ, Musisi S, Ram M, et al. Depression, alcohol 
use and adherence to antiretroviral therapy in sub-Saharan Africa: a systematic review. AIDS 
Behav. 2012; 16:2101–2118. [PubMed: 22116638] 
54. Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: 
review and meta-analysis. J Acquir Immune Defic Syndr. 2009; 52:180–202. [PubMed: 19668086] 
55. Katz IT, Ryu AE, Onuegbu AG, Psaros C, Weiser SD, Bangsberg DR, et al. Impact of HIV-related 
stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc. 2013; 
16:18640. [PubMed: 24242258] 
56. Patel R, Ratner J, Gore-Felton C, Kadzirange G, Woelk G, Katzenstein D. HIV disclosure patterns, 
predictors, and psychosocial correlates among HIV positive women in Zimbabwe. AIDS Care. 
2012; 24:358–368. [PubMed: 21902570] 
Denison et al. Page 12













57. Alonzo AA, Reynolds NR. Stigma, HIV and AIDS: an exploration and elaboration of a stigma 
trajectory. Soc Sci Med. 1995; 41:303–315. [PubMed: 7481925] 
58. Takada S, Weiser SD, Kumbakumba E, Muzoora C, Martin JN, Hunt PW, et al. The dynamic 
relationship between social support and HIV-related stigma in rural Uganda. Ann Behav Med. 
2014; 48:26–37. [PubMed: 24500077] 
59. Ware NC, Idoko J, Kaaya S, Biraro IA, Wyatt MA, Agbaji O, et al. Explaining adherence success 
in sub-Saharan Africa: an ethnographic study. PLoS Med. 2009; 6:e1000011.
60. O’Laughlin KN, Wyatt MA, Kaaya S, Bangsberg DR, Ware NC. How treatment partners help: 
social analysis of an African adherence support intervention. AIDS Behav. 2012; 16:1308–1315. 
[PubMed: 21947835] 
61. Mills EJ, Lester R, Ford N. Promoting long term adherence to antiretroviral treatment. BMJ. 2012; 
345:10.
62. Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF, et al. Adherence to 
antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income 
countries: a systematic review and meta-analysis. AIDS. 2012; 26:2039–2052. [PubMed: 
22951634] 
63. Matthews LT, Heffron R, Mugo NR, Cohen C, Hendrix C, Celum C, et al. High medication 
adherence during periconception periods among HIV-1-uninfected women participating in a 
clinical trial of antiretroviral preexposure prophylaxis. J Acquir Immune Defic Syndr. 2014; 
67:91–97. [PubMed: 25118795] 
64. Merten S, Kenter E, McKenzie O, Musheke M, Ntalasha H, Martin-Hilber A. Patient-reported 
barriers and drivers of adherence to antiretrovirals in sub-Saharan Africa: a meta-ethnography. 
Trop Med Int Health. 2010; 15:16–33. [PubMed: 20586957] 
65. Tsai AC, Bangsberg DR, Weiser SD. Harnessing poverty alleviation to reduce the stigma of HIV 
in sub-Saharan Africa. PLoS Med. 2013; 10:e1001557. [PubMed: 24319400] 
Denison et al. Page 13

























Denison et al. Page 14
Table 1















 Age (years) median (IQR) 41 (35–47) 39 (34–46) 40 (34–47) 40 (34–47) 39 (33–46)
Age: n (%)
 <35 years 350 (23.4) 406 (27.2) 395 (26.4) 1151 (25.6) 443 (29.6)*
 ≥35 years 1133 (75.6) 1028 (68.8) 1093 (73.1) 3254 (72.5) 1029 (68.7)
 Missing 15 (1.0) 61 (4.1) 8 (0.5) 84 (1.9) 25 (1.7)
Sex: n (%)
 Female 1096 (73.2) 982 (65.6) 968 (64.7) 3045 (67.8) 999 (66.7)
 Male 402 (26.8) 514 (34.4) 528 (35.3) 1444 (32.2) 498 (33.3)
Marital status: n (%)
 Single 204 (13.6) 116 (7.8) 122 (8.2) 442 (9.8) 149 (9.95)
 Separate/divorced/widowed 425 (28.4) 637 (42.6) 476 (31.8) 1538 (34.3) 496 (33.1)
 Married/cohabitating 863 (57.6) 734 (49.1) 898 (60.0) 2495 (55.6) 850 (56.8)
 Missing 6 (0.4) 8 (0.5) 0 (0.0) 14 (0.3) 2 (0.1)
ART characteristics
Length of time on ART: n (%)
 <2.2 years 425 (28.4) 373 (24.9) 304 (20.3) 1102 (24.5) 316 (21.1)*
 2.2–5.3 years 739 (52.9) 735 (49.2) 721 (48.2) 2249 (50.1) 774 (51.7)
 >5.3 years 280 (18.7) 387 (25.9) 471 (31.5) 1138 (25.4) 407 (27.2)
Current ART regimen: n (%)
 D4T, 3TC, NVP 561 (37.4) 11 (0.7) 159 (10.6) 731 (16.3) 321 (21.4)*
 TDF, 3TC/FTC, EFV 116 (7.7) 86 (5.8) 498 (33.3) 700 (15.6) 263 (17.5)
 ZDV, 3TC, EFV 396 (26.4) 300 (20.1) 78 (5.2) 774 (17.2) 271 (18.1)
 ZDV, 3TC, NVP 262 (17.5) 909 (60.8) 256 (17.1) 1427 (31.8) 418 (27.9)
 Other regimens 70 (4.7) 175 (11.7) 437 (29.2) 682 (15.2) 198 (13.2)
 Missing 93 (6.2) 14 (0.9) 68 (4.5) 175 (3.9) 26 (1.7)
CD4+ cell count prior to ART: n (%)
 >250 cells/μl 213 (14.2) 111 (7.4) 243 (16.2) 567 (12.6) 198 (13.2)
 ≤250 cells/μl 995 (66.4) 1087 (72.7) 938 (62.7) 3020 (67.3) 989 (66.1)
 Missing 290 (19.4) 297 (19.9) 315 (21.1) 902 (20.1) 310 (20.7)
3TC, lamivudine; D4T, stavudine; EFV, efavirenz; FTC, emtricitabine; IQR, interquartile range; NVP, nevirapine; TDF, tenofovir; VL, viral load; 
ZDV, zidovudine.
*
P<0.05 comparing the subset of participants from VL testing sites to the total study sample.
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Table 2
Number of individuals with incomplete adherence by the different adherence measures and standardized cut-
off points among adults in selected antiretroviral treatment programs in Tanzania, Uganda and Zambia, 2011.
Complete population Sample from sites with
VL measurements
Cut-off n/N a % less than the cut-off n/N b %
Self-reported adherence measures
 % ARV drugs missed – last 3 days 100% 249/4299 5.8 109/1470 7.4
95% 249/4299 5.8 109/1470 7.4
90% 235/4299 5.5 106/1470 7.2
80% 130/4299 3.0 55/1470 3.7
 % ARV drugs missed – last 30 days 100% 517/4289 12.1 239/1460 16.4
95% 113/4289 2.6 43/1460 2.9
90% 46/4289 1.1 14/1460 1.0
80% 22/4289 0.5 8/1460 0.5
 % ARV drugs missed – visual analogue
 scale, last 30 days
100% 2599/4450 58.4 682/1484 46.0
95% 1730/4450 38.9 427/1484 28.8
90% 1119/4450 25.1 253/1484 17.0
80% 511/4450 11.5 85/1484 5.7
 Case Adherence Index >10 751/4473 16.8 304/1493 20.4
 Missed ≥48 consecutive hours of
  ARV drugs in last 3 months
Yes 141/4425 3.2 64/1471 4.4
Other adherence measures
 Healthcare provider report 100% 3150/4415 71.3 792/1463 54.1
95% 1835/4415 41.6 476/1463 32.5
90% 1236/4415 28.0 302/1463 20.6
80% 594/4415 13.5 157/1463 10.7
 Pharmacy medication possession
  ratio (MPR)
100% 3261/4070 80.1 1275/1450 87.9
95% 2131/4070 52.4 837/1450 57.7
90% 1634/4070 40.1 659/1450 45.4
80% 979/4070 24.1 429/1450 29.6
a
Number nonadherent/total number of individuals with data in the population. ARV, antiretroviral.
b
The denominators for these adherence measures vary due to missing data mainly on the current ART regimen and associated daily pill burden 
needed to calculate adherence.
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Table 3
Association between adherence measures and virologic failure at least 1000 copies/ml among adults in 
selected antiretroviral treatment programmes in Tanzania, Uganda and Zambia, 2011.
Patients with virologic failure ≥1000 copies/ml
n/N a OR (95% CI)b P *
Self-reported adherence measuresc
% ARV drugs missed – last 3 days
 <93% 12/107 (11.2%) 1.28 (0.68–2.42) 0.450
 ≥93% 132/1363 (9.7%)
% ARV drugs missed – last 30 days
 <99% 22/237 (9.3%) 1.04 (0.63–1.69) 0.888
 ≥99% 122/1223 (10.0%)
% ARV drugs missed – visual analogue scale – last 30 days
 <99% 68/633 (10.7%) 0.86 (0.57–1.30) 0.479
 ≥99% 80/851 (9.4%)
CASE Adherence Index
 <11 33/304 (10.9%) 1.30 (0.84–2.01) 0.233
 ≥11 115/1189 (9.7%)
Missed ≥48 consecutive hours of ARV drugs in past 3 months
 ≥48 h 16/64 (25.0%) 2.86 (1.56–5.26) 0.001
 <48 h 128/1407 (9.1%)
Other adherence measures
Healthcare provider report
 <98% 82/628 (13.1%) 1.57 (1.02–2.41) 0.042
 ≥98% 60/835 (7.2%)
Pharmacy medication possession ratio (MPR)
 <90% 72/659 (10.9%) 1.48 (1.02–2.15) 0.037
 ≥90% 67/791 (8.5%)
ARV, antiretroviral; CI, confidence interval; OR, odds ratio.
a
N, number of patients in subgroup; n, number of failures in subgroup.
b
OR of failure among incomplete-adherent versus adherent patients from logistic regression.
c
Cut-off points determined by receiver operator curve (ROC) analysis.
*
P for association between adherence measure and failure, adjusted for ART study site.
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Table 4
Bivariate analysis of missed at least 48 consecutive hours of antiretroviral therapy in the past 3 months among 
adults in selected antiretroviral treatment programmes in Tanzania, Uganda and Zambia, 2011.







 <35 1128 26.0 26.0 26.2 0.97 (0.66–1.43) 0.867
 ≥35 years 3215 74.0 74.0 73.8 1
 Missing 82 82 0
Female sex 3006 67.9 68.2 61.0 0.72 (0.51–1.02) 0.065
Marital status
 Single 434 9.8 9.7 12.8 1.54 (0.90–2.63) 0.227
 Separated/divorced/widowed 1523 34.5 34.4 37.6 1.24 (0.86–1.80)
 Married or cohabiting 2456 55.7 55.9 49.6 1
 Missing 12 12 0
DHS Wealth Index
 Low 1473 33.3 33.4 31.2 0.79 (0.50–1.25) 0.579
 Middle 1476 33.4 33.4 31.9 0.86 (0.56–1.31)
 High 1476 33.4 33.2 36.9 1
Psychosocial factors
Stigma internalized
 High (>median) 1540 34.8 34.3 49.6 1.63 (1.15–2.32) <0.006
 Low 2883 65.2 65.7 50.4 1
 Missing 2 2 0
Stigma disclosure
 High (>median) 1212 27.4 27.5 25.5 0.92 (0.59–1.44) <0.728
 Low 3211 72.6 72.5 74.5 1
 Missing 2 2 0
Potential depression
 Positive screen 574 13.0 12.6 23.4 1.89 (1.25–2.87) 0.003
 Negative screen 3847 87.0 87.4 76.6 1
 Missing 4 4 0
Ever-disclosed HIV status
 Yes 4154 94.0 94.0 92.9 0.90 (0.45–1.79) 0.771
 No 267 6.00 6.00 7.10 1
 Missing 4 4 0
Social support care
 Lower 10th percentile 513 11.7 11.4 20.0 1.71 (1.10–2.67) 0.017
 Higher 3865 88.3 88.6 80.0 1
 Missing 48 47 1
Social support help
 Lower 10th percentile 595 13.6 13.5 17.1 1.23 (0.77–1.95) 0.387
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 Higher 3782 86.4 86.5 82.9 1
 Missing 48 47 1
CAGE alcohol abuse
 Positive ≥2 930 21.2 20.8 34.3 1.87 (1.29–2.70) <0.001
 Negative<2 3448 78.8 79.2 65.7 1
 Missing 47 46 1
Traditional healer
 Ever consulted 253 5.8 5.4 15.6 2.67 (1.55–4.60) <0.001
 Never consulted 4136 94.2 94.6 84.4 1
 Missing 36 36 0
Cost to clinic
 ≥1 USD 1924 45.9 46.0 41.5 0.82 (0.56–1.20) 0.310
 <1 USD 2269 54.1 54.0 58.5 1
 Missing 232 226 6
Time to clinic
 ≥30 min 2298 52.0 51.9 52.5 0.93 (0.65,1.34) 0.694
 <30 min 2215 48.0 48.1 47.5 1
 Missing 2 2 0
ART and clinical factors
ART regimens containing
 EVF 1540 34.8 34.7 38.3 1.35 (0.94–1.95) 0.103
 NVP 2567 58.0 58.3 48.9 0.57 (0.40–0.81) 0.002
 ZDV 2224 50.3 50.2 51.8 0.85 (0.58–1.25) 0.410
 TDF 1131 25.6 25.7 20.6 0.95 (0.60–1.50) 0.823
 D4T 805 18.2 18.2 17.0 0.84 (0.50–1.39) 0.490
 FTC 1020 23.1 23.2 17.7 0.92 (0.56–1.51) 0.752
 3TC 3191 72.1 72.1 72.3 0.72 (0.47–1.11) 0.141
 PI 136 3.10 3.10 3.50 1.13 (0.45–2.86) 0.798
Time on ART
 <2.2 1089 24.6 24.5 27.7 1.18 (0.73–1.90) 0.597
 2.2–5.3 2213 50.0 50.1 46.8 0.96 (0.62–1.46)
 >5.3 1123 25.4 25.4 25.5
Pill burden (self-report)
 <4 3510 81.3 81.2 84.7 1.15 (0.70–1.90) 0.578
 ≥4 809 18.7 18.8 15.3 1
 Missing 106 96 10
HIV symptom index (≥ median) 2458 55.5 55.0 73.0 1.98 (1.34–2.94) <0.001
Pre-ART WHO stage
 Missing 381 8.6 8.7 7.1 0.95 (0.47–1.95) 0.144
 Stage IV 517 11.7 11.4 19.1 1.74 (1.02–2.96)
 Stage III 1842 41.6 41.6 42.6 1.38 (0.92–2.09)
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 Stage I and II 1685 38.1 38.3 31.2
Pre-ART CD4+ cell count (cells/μl)
 Missing 889 20.1 20.0 22.0 1.11 (0.73–1.69) .038
 >250 558 12.6 12.7 9.2 0.69 (0.38–1.26)
 ≤250 2978 67.3 67.3 68.8 1
Site-level factors
Buddy required to start ART (yes) 3440 77.7 77.5 85.1 1.51 (0.54–4.21) 0.4051
Community ART dispensing (yes) 1228 27.8 28.0 19.9 0.53 (0.20–1.39) 0.182
ART dispensing in clinic 2823 63.8 63.4 74.5 1.54 (0.66–3.60) 0.301
ART refill frequency
 Every 3 months 1224 27.7 27.3 39.0 3.15 (0.41–4.11) 0.152
 Every 2 months 2217 50.1 50.1 49.6 2.35 (0.77–7.19)
 Every month 984 22.2 22.6 11.3 1
Level of health facility
 National 732 16.5 16.4 21.3 1.30 (0.41–4.11) 0.174
 Provincial/regional 983 22.2 21.9 30.5 1.22 (0.39–3.79)
 District 1480 33.4 34.0 17.7 0.42 (0.14–1.26)
 Primary/community 1230 27.8 27.7 30.5 1
Type of health facility
 Government 2467 55.8 56.4 36.2 0.40 (0.16–1.00) 0.086
 Mission 976 22.1 21.8 31.2 0.84 (0.30–2.39)
 NGO 982 22.2 21.8 32.6 1
Health facility size
 <1000 on ART 1344 30.4 30.3 31.9 1.05 (0.28–3.95) 0.955
 1000–2000 370 8.4 8.4 7.1 1.20 (0.20–7.07)
 2000–4000 1723 38.9 38.8 41.8 1.34 (0.38–4.72)
 >4000 988 22.3 22.4 19.1 1
Locale
 Nonurban 1470 33.2 33.5 26.2 0.49 (0.19–1.22) 0.118
 Urban 2955 66.8 66.5 73.8 1
Lay person provides adherence 
counselling 3566 80.6 80.6 80.1 0.86 (0.30–2.42) 0.758
ART stock out past 6 months 497 11.2 11.4 5.0 0.41 (0.10–1.72) 0.209
3TC, lamivudine; ART, antiretroviral therapy; CI, confidence interval; D4T, stavudine; DHS, demographic and health survey; EFV, efavirenz; 
FTC, emtricitabine; NGO, nongovernmental organization; NVP, nevirapine; PI, protease inhibitors; TDF, tenofovir; USD, United States dollar; 
ZDV, zidovudine.
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Table 5
Final multivariable model for factors associated with incomplete adherence: missed at least 48 consecutive 
hours of antiretroviral drugs among adults in selected antiretroviral treatment programmes in Tanzania, 
Uganda and Zambia, 2011.
Adjusted odds ratio
(95% CI) P
Internalized stigma: high 1.50 (1.05–2.13) 0.025
Social support care: low 1.55 (0.99–2.43) 0.054
Alcohol abuse: positive 1.68 (1.16–2.44) 0.006
HIV symptoms: high 1.79 (1.20–2.67) 0.004
Traditional medicine: ever visited 2.41 (1.39–4.18) 0.002
ART regimen includes NVP: Yes 0.60 (0.42–0.85) 0.005
ART, antiretroviral treatment; CI, confidence interval; NVP, nevirapine.
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